Shopping Cart
- Remove All
- Your shopping cart is currently empty
N-Oleoyl glycine, a lipoamino acid, was able to promote 3T3-L1 adipogenesis through the activation of CB1 receptor and the enhancement of insulin-mediated Akt signaling pathway.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $39 | In Stock | |
10 mg | $64 | In Stock | |
25 mg | $98 | In Stock | |
50 mg | $153 | In Stock | |
100 mg | $229 | In Stock | |
200 mg | $342 | In Stock | |
1 mL x 10 mM (in DMSO) | $70 | In Stock |
Description | N-Oleoyl Glycine, a Lipoamino Acid, Stimulates Adipogenesis Associated With Activation of CB1 Receptor and Akt Signaling Pathway in 3T3-L1 Adipocyte |
In vitro | N-Oleoyl glycine stimulated lipid accumulation and significantly increased adipogenic genes (PPARγ and aP2), in a dose- and time-dependent manner.?Additionally, N-Oleoyl glycine markedly increased the mRNA expression of CB1 receptor and the inhibition of CB1R by its antagonist SR141716 abolished the promotive effects of N-Oleoyl glycine on lipid accumulation and the protein expression of PPARγ and aP2.?Furthermore, N-Oleoyl glycine increased the ratio of p-Akt/Akt and p-FoxO1/FoxO1, which could be reversed by SR141716.?Moreover, N-Oleoyl glycine-induced enhancement of adipogenesis, activation of insulin-mediated Akt signaling pathway and inactivation of FoxO1 were effectively blocked by Wortmannin, a specific PI3K/Akt inhibitor, indicating the essential role of Akt signaling pathway in the process of N-Oleoyl glycine-stimulated 3T3-L1 adipogenesis[1]. |
Molecular Weight | 339.51 |
Formula | C20H37NO3 |
Cas No. | 2601-90-3 |
Smiles | CCCCCCCC\C=C/CCCCCCCC(=O)NCC(O)=O |
Relative Density. | 0.962g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (235.63 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.